# Senior Director, Team Lead, KAT6i (Prifetrastat), US Breast Cancer — Pfizer

- Location: United States
- Posted pay: $215k–$358k/yr
- Posted: Nov 16, 2026
- Status: open (checked Nov 21, 2026)
- Apply (employer's site): https://pfizer.wd1.myworkdayjobs.com/InternalJobs/job/United-States---New-York---New-York-City/Senior-Director--Team-Lead--KAT6i--Prifetrastat---US-Breast-Cancer_4968032
- Employer record: https://visajobs.io/company/pfizer.md

## Sponsorship history
- Tier: Employer history only
- With this exact title: 0

## Description
ROLE SUMMARY
Pfizer Commercial Oncology is introducing the world to the next era of cancer care. With a growing portfolio of novel therapies, industry-leading R&D, and a goal of delivering eight breakthroughs by 2030 across major cancer types, we're translating cutting-edge science into market-shaping impact. Here, you'll partner with exceptional colleagues across scientific, medical, and manufacturing teams, backed by advanced digital and AI-enabled infrastructure and the authority to accelerate medicines from discovery to delivery. Guided by our values of courage, excellence, equity, and joy, you'll have the opportunity to stretch your skills and build a career that evolves with you—across teams, roles, and the Pfizer enterprise. Join us to make history — for patients, for their families, for the future.
Breast cancer is the most common cancer affecting women in the US, and Pfizer has led the HR+ metastatic breast cancer market for a decade with IBRANCE, our first-in-class CDK 4/6 inhibitor. We are now building the next generation of breast cancer medicines, including prifetrastat (PF-07248144), our first-in-class KAT6 inhibitor in Phase 3 for HR+/HER2- advanced breast cancer after prior CDK4/6 inhibitor therapy.
The next three years are the most consequential in the history of Pfizer’s breast cancer business. As IBRANCE moves through IRA effectuation and LOE in 2027, prifetrastat is the franchise’s first opportunity to extend its leadership into the post-CDK4/6 setting, where the landscape is fragmented and no established playbook exists. This role builds the commercial foundation for prifetrastat so that customers, accounts and the field are ready when it reaches the market, and ensures its strategy connects to the first-line CDK franchise.
ROLE RESPONSIBILITIES
This Senior Director, Team Lead role reports to the VP, US Breast Cancer Franchise Lead and is an excellent opportunity for an experienced, collaborative and innovative leader to build a launch from the ground up. The role owns US launch preparation for prifetrastat and leads a team of up to 3–4 marketers at the Director and Sr. Manager level, including a dedicated launch lead.
1. Build the prifetrastat launch foundation
Own the prifetrastat pre-launch P&L and launch budget: build the long-range forecast and investment case, manage OpEx and resource allocation through launch, and establish the financial discipline the brand will carry into its first years on the mark
Lead US commercial strategy in a complex shifting landscape for prifetrastat, including target product profile input, positioning, segmentation, target customers and the HCP and account launch plan.
Assess the market landscape with CtDNA & competitive entrants into the post-CDK 4/6 treatment paradigm
Shape the market ahead of approval with disease-state education on post-CDK4/6 progression and KAT6 biology, and pre-launch engagement with key customers and advocacy groups, in partnership with Medical Affairs and Patient Advocacy.
Turn the brand strategy into workstreams that address the launch-critical issues: differentiation in a fragmented post-CDK4/6 landscape, biomarker testing readiness, tolerability and dose-management support for clinicians and patients, and customer value.
Define launch-readiness milestones, evidence needs and the investment case in partnership with Clinical Development, Market Access, Commercial Insights and Sales.
2. Build access and the patient foundation
Partner with Market Access, Pricing and Trade to shape the prifetrastat pricing and contracting strategy, channel and distribution model, and gross-to-net plan, ensuring the launch is positioned for durable access and profitability.
Build the prifetrastat patient and advocacy strategy from the start, including DTC/DTP, patient support and adherence programs, with tolerability and dose management designed in for both HCPs and patients.
3. Connect the launch to the franchise
Map the patient journey from first-line CDK4/6 inhibitor use to post-CDK4/6 treatment so the IBRANCE, atirmociclib and prifetrastat strategies reinforce each other.
Align with BC Sales and KAD leadership on how prifetrastat enters annual POAs and field focus, incorporating CFC (customer facing colleague) feedback as the portfolio changes.
Lead the prifetrastat customer insight plan in partnership with analytics, CFCs and cross-functional partners, and use it to evolve the strategic and tactical approach and anticipate how HCPs will sequence therapy after CDK4/6 progression.
Drive innovation and build new approaches from the ground up where no established playbook exists, with a particular focus on AI and the go-to-market model.
4. Lead people and the franchise
Manage, engage and coach the team to achieve high performance and maximize team potential, and plan roles, development and succession as the team scales toward launch.
Actively foster a positive team culture and collaboration across the broader US BC marketing team.
Participate in leadership presentations, performance updates and OpEx management to maintain Pfizer’s Breast Cancer leadership for the next decade.
BASIC QUALIFICATIONS
Candidate demonstrates a breadth of diverse leadership experiences and capabilities including the ability to influence and collaborate with peers, develop and coach others, and oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
Bachelor’s degree required and 12+ years of pharmaceutical industry experience required, or Master's degree and 10+ years, or Ph.D./PharmD
US marketing experience with focus on HCP stakeholders, including pre-launch or launch work
Deep understanding of US market dynamics including specialty channels, organized customers and payers
Demonstrated success developing, executing and measuring complex marketing programs and championing innovative solutions
COMMERCIAL EXCELLENCE: Proven track record of identifying customer needs and extracting and translating key 

> History, not a promise: past H-1B filings do not mean an employer will sponsor you or a given role. Data: U.S. DOL OFLC LCA disclosure (FY2024–FY2026 for role counts, certified LCAs) and the USCIS H-1B Employer Data Hub. Not legal advice. Methodology: https://visajobs.io/methodology
